Home
Hirotsu Bio Science

Hirotsu Bio Science Market Share Analysis for June 2026

HIROTSUバイオサイエンスは線虫がん検査に関する世界最先端の線虫行動解析技術と臨床研究成果で、がん早期発見の実現に貢献します。現在、がん検査は、PET‐CT、エコー、MRI、CT、5大がん検査などが存在しますが、「安価」「簡便」「高精度」という条件を満たした〝最初に受けるがん検査〟は存在していません。しかし線虫がん検査N‐NOSEは、そのいずれも満たしたがん検査です

Business and Consumer Services > Printing & Self Publishing

Domainhbio.jp

Year Founded--

Employees51 - 200

Annual Revenue--

Hirotsu Bio Science

Hirotsu Bio Science (including company regionals)

hbio.jp

See more website traffic and engagement information

Total visits to Hirotsu Bio Science's top domains

Understand Hirotsu Bio Science market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

hbio.jp11.3K

See more with Sales Intelligence

Avg. visit duration in Hirotsu Bio Science's top domains

Analyze Hirotsu Bio Science engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

hbio.jp00:01:12

See more with Sales Intelligence

Avg. pageviews on Hirotsu Bio Science's top domains

See how Hirotsu Bio Science keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

hbio.jp1.68

See more with Sales Intelligence

Hirotsu Bio Science top competitors by domain

Top similar sites in June 2026, ranked by their affinity

biocartis.comCompany NameBiocartisEmployees201 - 500HQBelgium, MechelenAnnual revenue$50M - $75MTotal visits9.1KHealth > Biotechnology and Pharmaceuticals

Top technologies used by Hirotsu Bio Science

These are the website technologies, by industry, used by Hirotsu Bio Science top domains

Advertising (17)

Google Adsense

Conversion & Analytics (5)

Google Analytics

Mobile (3)

Meta Viewport

Widget (3)

Twemoji

More Technologies

9

See all

News & Signals from Hirotsu Bio Science

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsHirotsu Bio Science Inc. launched N-NOSE plus Pancreas service on Jan 1st '22.In 2022, Hirotsu Bio Science Inc. launched the "N-NOSE plus Pancreas" service, the world's first cancer-specific test capable of detecting early-stage pancreatic cancer, which will play the next role in early cancer detection.

NewsHirotsu Bio Science Inc. received financing of $9.45M in equity round of funding on Jul 23rd '18.Hirotsu Bio Science Inc. announced that it has received ¥1.4 billion in its equity round of funding on July 23, 2018.